Table 2.
Recurrently mutated genes in cancers, including hematologic malignancies, for which possible or definite public neoantigens have been identified.
| Gene/gene family | Overall prevalence of any mutation in the gene/gene family in human cancers | Prevalence of any mutation in the gene/gene family in hematologic malignancies | Mutation hotspots (all cancers including hematologic) | Mutations yielding possible/definite neoantigens* | References |
|---|---|---|---|---|---|
| KRAS/NRAS/HRAS | ~25% (all RAS genes) | ~26% multiple myeloma | G12, G13, Q61 | G12D, G12V | (146, 148, 149). |
| ~16% AML | |||||
| ~14% ALL | |||||
| ~10% CLL | |||||
| ~5% MDS (~30% CMML) | |||||
| BRAF | ~8% | ~100% hairy cell leukemia | V600 | V600E | (148, 150–154) |
| ~40–60% systemic histiocytoses | |||||
| ~5% CLL | |||||
| TP53 | ~25% | 14% AL | R175, R245, R248, R273, R282 | R175H, R248Q, R248W, R282W | (99–101, 155) |
| 12% AML | |||||
| 7–10% CLL | |||||
| 6% MDS | |||||
| 6–24% B cell lymphoma | |||||
| 7–40% non-B cell lymphoma | |||||
| 6% myeloma and other plasma cell dyscrasias |
*
See Table 1 for specific details about neoantigens.